grant
Reversing Graft Rejection by Targeting Innate Immune Memory with Novel Nanobiologics
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 2 Feb 2026Deadline 31 Jan 2028
NIHUS FederalResearch GrantFY202670-kD Heat-Shock ProteinAcuteAddressAllogenicAllograftingBlood monocyteCell BodyCell Communication and SignalingCell SignalingCellsChronicClinicalDataDrugsFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2Graft RejectionGraft SurvivalHSP 70HSP70HealthHeat-Shock Proteins 70ImmuneImmune Modulation TherapyImmune TargetingImmune memoryImmunesImmunityImmunobiologyImmunologic MemoryImmunological MemoryImmunophysiologyImmunosuppressantsImmunosuppressionImmunosuppression EffectImmunosuppressive AgentsImmunosuppressive EffectImmunosuppressive drugImmunosuppressive treatmentInflammationInflammatory ResponseInnate Immune ResponseIntracellular Communication and SignalingKO miceKnock-out MiceKnockout MiceMarrow monocyteMechanistic Target of RapamycinMediatingMedicationMiceMice MammalsModelingMolecular TargetMurineMusNull MouseOutcomePathway interactionsPatientsPharmaceutical PreparationsQOLQuality of lifeRAFT1RapamuneRapamycinRegimenRisk FactorsRoleSignal TransductionSignal Transduction SystemsSignalingSirolimusT-CellsT-LymphocyteTestingTherapeuticTrainingTransplant RecipientsTransplant RejectionTransplantationTransplantation RejectionTreatment EfficacyUniversitiesallograft rejectionanamnestic reactionbiological signal transductiondrug/agenthsp70 Familyimmune modulatory therapiesimmune modulatory treatmentimmune regulation therapyimmune regulation treatmentimmune regulatory therapyimmune suppressionimmune suppressive activityimmune suppressive agentimmune suppressive functionimmune suppressorimmune-modulation treatmentimmunomodulation therapyimmunomodulation treatmentimmunomodulator therapiesimmunomodulator treatmentimmunomodulator-based therapiesimmunomodulatory biologicsimmunomodulatory therapiesimmunomodulatory treatmentimmunoregulatory therapyimmunoregulatory treatmentimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunosuppressive substanceimmunosuppressorimprovedinhibitorintervention efficacyislet allograftmTORmTOR InhibitormTOR inhibitionmammalian target of rapamycinmonocytemouse modelmultiomicsmultiple omicsmurine modelnano-biologicalnanobiologicnanobiological particlenanotherapeuticnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovelnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyorgan rejectionorgan transplant rejectionpanomicspathwaypreventpreventingresponsesecondary immune responsesocial roletherapeutic efficacytherapeutic immunomodulationtherapeutic immunoregulationtherapy efficacythymus derived lymphocytetransplanttransplant patient
Description preview
PROJECT SUMMARY
A key risk factor to long-term outcomes is persistent and reoccurring early acute T cell mediated rejection
(TCMR) episodes, which occur in a significant fraction of patients despite rejection treatment. Thus, a key
deficit in the field is a lack of available immunomodulating therapeutics that both effectively control
acute TCMR…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click